Parallel is a skin health company providing personalized precision skincare, skin microbiome testing, clinical expertise, and personalized prescriptions to support aging, acne, eczema, rosacea, melasma, and hidradenitis suppurativa.
Broad antimicrobials may disrupt helpful microbes and fail to address the specific organisms associated with an individual skin condition
R&D Focus
Whole-genome skin microbiome sequencing, AI selection and bacteriophage-based precision skincare
Innovative Solution
Sequences a user’s skin microbiome and selects targeted phages for a personalized topical serum such as MD-03
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$1.85M
Last Funding Amount
$1.1M
Startup Stage
Early Stage
Lead Investors
Ecotone Fund, First In Ventures, Kevin Moore, Rhythm VC, StartX (US)
People
Founders
Natalise Kalea Robinson
Nathan Brown
CEO
Natalise Kalea Robinson
About
Parallel is a skin health company providing personalized precision skincare, skin microbiome testing, clinical expertise, and personalized prescriptions to support aging, acne, eczema, rosacea, melasma, and hidradenitis suppurativa.
Products
Product
Skin Discovery Test and customized phage serum/MD-03 programs; conventional consumer-review volume is limited
Star Product
Skin Discovery Test plus personalized phage serum, because the diagnostic and treatment-selection steps work together
Demo Product or Complete Product?
Pilot or early-commercial precision-dermatology service; emerged publicly in 2023
Future Plan
Market Expansion
Professional and clinician channels are the main expansion route
Investment Funding
$2.3M pre-seed funding reported
Awards and Recognitions
Media Apperance
Covered by TechCrunch and biotechnology media
M&A and Collabs
Collab
Works with clinicians and dermatology practices for testing and treatment programs
Collab
Engages sequencing and laboratory partners within the microbiome workflow
Something missing or incorrect on this page? Help us enrich this information
